84499-73-0

Basic information

• Product Name: (S)-1-[4-(Trifluoromethyl)phenyl]ethylamine
• Synonyms: S-PTF-PEM;(S)-1-[4-(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE;(S)-1-(4-(TRIFLUOROMETHYL)PHENYL)ETHANAMINE;(1S)-1-[4-(Trifluoromethyl)phenyl]ethylamine;Benzenemethanamine, α-methyl-4-(trifluoromethyl)-, (αS)-;Benzenemethanamine, .alpha.-methyl-4-(trifluoromethyl)-, (.alpha.S)-;(S)-alpha-Methyl-4-(trifluoromethyl)benzylamine;(S)-1-[4-(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE-HCl
• CAS NO: 84499-73-0
• Molecular Formula: C₉H₁₀F₃N
• Molecular Weight: 189.18
• Product Categories: intermediates
• Mol File: 84499-73-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 203.9 °C at 760 mmHg
• Flash Point: 82.9 °C
• Appearance: /
• Density: 1.18 g/cm³
• Vapor Pressure: 5.09mmHg at 25°C
• Refractive Index: 1.285
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: (S)-1-[4-(Trifluoromethyl)phenyl]ethylamine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-[4-(Trifluoromethyl)phenyl]ethylamine(84499-73-0)
• EPA Substance Registry System: (S)-1-[4-(Trifluoromethyl)phenyl]ethylamine(84499-73-0)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 84499-73-0(Hazardous Substances Data)

Usage

General Description

(S)-1-[4-(Trifluoromethyl)phenyl]ethylamine is a chemical compound with a molecular formula C10H12F3N. It is an organic compound that belongs to the class of amines, which are derivatives of ammonia where one or more hydrogen atoms are replaced by organic substituents. In this particular compound, the amine group is attached to a phenyl ring with a trifluoromethyl substituent at the 4-position, and an ethyl group at the alpha position. (S)-1-[4-(Trifluoromethyl)phenyl]ethylamine is commonly used in pharmaceutical research and drug development due to its potential pharmacological properties and its ability to serve as a precursor for the synthesis of various biologically active compounds. Additionally, it may also be used in organic synthesis as a building block for the creation of more complex molecules.

InChI:InChI=1/C10H2F18/c11-3(12,5(15,16)7(19,20)9(23,24)25)1-2-4(13,14)6(17,18)8(21,22)10(26,27)28/h1-2H/b2-1+

Upstream product

• 84499-82-1 (S)-2-Acetylamino-4-methyl-pentanoic acid; compound with (S)-1-(4-trifluoromethyl-phenyl)-ethylamine 
• 437762-12-4 (S)-1-phenyl-N-((S)-1-(4-(trifluoromethyl)phenyl)ethyl)ethan-1-amine 
• 581812-91-1 (S)-N-[α-methyl-4-(trifluoromethyl)benzyl] (R)-2-acetoxy-2-phenylethanamide 
• 709-63-7 1-(4-trifluoromethylphenyl)ethanone 
• 15996-84-6 1-(4-trifluoromethylphenyl)ethylamine 
• 107496-43-5 1-(4-(trifluoromethyl)phenyl)ethan-1-one O-methyl oxime 
• 672906-91-1 (E)-N-(1-(S)-phenylethyl)ethan-1-(4-(trifluoromethyl)phenyl)-1-imine 
• 444643-05-4 ((S)-1-Phenyl-ethyl)-[(R)-1-(4-trifluoromethyl-phenyl)-ethyl]-amine 
• 1737-26-4 1-(4-trifluorophenyl)ethanol 

Downstream Products

• 870709-68-5 5-isopropyl-2-((S)-1-(4-(trifluoromethyl)phenyl)-ethylamino)thiazol-4(5H)-one 
• 1073722-50-5 C₁₄H₁₆F₃NO 
• 1246387-29-0 1-[4-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzoyl]-4-phenyl-piperidine-4-carboxylic acid [(S)-1-(4-trifluoromethyl-phenyl)-ethyl]-amide 
• 1256476-02-4 6-(tert-butoxycarbonyl)-2-(S)-{1-[4-(trifluoromethyl)phenyl]ethylamino}-3-propargyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-4-(3H)-one 
• 1256476-05-7 6-(tert-butoxycarbonyl)-2-(S)-{1-[4-(trifluoromethyl)phenyl]ethylamino}-3-dimethylamino-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-(3H)-one 
• 1256476-09-1 6-(tert-butoxycarbonyl)-2-(S)-{1-[4-(trifluoromethyl)phenyl]ethylamino}-3-methoxy-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-(3H)-one 
• 1256476-23-9 (S)-tert-butyl 4-oxo-3-(pyrrolidin-1-yl)-2-{1-[4-(trifluoromethyl)phenyl]ethylamino}-3,4,7,8-tetrahydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate 
• 1146245-82-0 C₂₄H₂₂F₃N₅O 
• 1362627-39-1 C₂₃H₂₉F₃N₂O₃ 

Relevant articles and documents

BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Trading N and O. Part 3: Synthesis of 1,2,3,4-tetrahydroisoquinolines from α-hydroxy-β-amino esters

A range of enantiopure 1,2,3,4-tetrahydroisoquinolines have been prepared directly from α-hydroxy-β-amino esters. Activation of the α-hydroxy group upon treatment with Tf2O and 2,6-di-tert-butyl-4-methylpyridine promotes aziridinium formation,

α-Methylation at benzylic fragment of N-aryl-N′-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model

SAR studies for N-aryl-N′-benzyl urea class of TRPV1 antagonists have been extended to cover α-benzyl alkylation. Alkylated compounds showed weaker in vitro potencies in blocking capsaicin activation of TRPV1 receptor, but possessed improved pharmacokinetic properties. Further structural manipulations that included replacement of isoquinoline core with indazole and isolation of single enantiomer led to TRPV1 antagonists like (R)-16a with superior pharmacokinetic properties and greater potency in animal model of inflammatory pain.